StreetAlpha.app
Home › Stocks › BIIB

Biogen Inc. (BIIB)

Healthcare
$249.59
▲ +1.00%
LAST CLOSE · NOV 20

Biogen is a Cambridge, Massachusetts biopharmaceutical company that develops and sells medicines for neurology and rare diseases. It last closed at $249.59 on Nov 20, up 1.00% on the day. The next earnings report for BIIB is expected around Tue, Jan 12, 2027, after the close. For the quarter ended Sep 2026, BIIB reported EPS of -$0.14 on revenue of $2.80B, with revenue up 10.6% from a year ago. Over its last 8 reports the stock moved an average of 2.9% the session after earnings. Over the last 12 months BIIB insiders bought $585 of stock on the open market and sold $905K, according to SEC Form 4 filings.

AI Auto Pilots
Is BIIB in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold BIIB.

Key Stats

Last 12 months
Results
Revenue
$10.3B
+2.3% vs a year ago
Net income
$347.5M
−78.4% vs a year ago
EPS (diluted)
$2.31
−78.9% vs a year ago
Free cash flow
$2.1B
20.1% margin
Valuation
Market cap
$36.9B
147.8M shares
P/E
108.0
Price over 12 month EPS
Price to sales
3.6
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$1.3B
At Sep 30
Debt
$7.3B
At Sep 30
Shares outstanding
147.8M
At Oct 26
CEOMichel Vounatsos
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: $11.0B$11.0BFY2021FY2022: $10.2B$10.2BFY2022FY2023: $9.8B$9.8BFY2023FY2024: $9.7B$9.7BFY2024FY2025: $9.9B$9.9BFY2025

From BIIB's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Oct 28). Last 12 months adds up the four latest quarters.

Next report
Jan 12
Estimated date · After the close
Reported EPS
-$0.14
Quarter ended Sep 2026
Year ago EPS
$3.17
−104.4% on a GAAP basis
Revenue
$2.80B
+10.6% vs a year ago
Estimates and implied move
Consensus forecasts and the move options price in
EPS by quarter (GAAP)
Dec 2024: $1.83Dec '24Mar 2025: $1.64Mar '25Jun 2025: $4.33Jun '25Sep 2025: $3.17Sep '25Dec 2025: -$0.35Dec '25Mar 2026: $2.15Mar '26Jun 2026: $0.66Jun '26Sep 2026: -$0.14Sep '26Latest -$0.14
Revenue by quarter
Dec 2024: $2.45BDec '24Mar 2025: $2.43BMar '25Jun 2025: $2.65BJun '25Sep 2025: $2.53BSep '25Dec 2025: $2.28BDec '25Mar 2026: $2.48BMar '26Jun 2026: $2.74BJun '26Sep 2026: $2.80BSep '26Latest $2.80B
How BIIB moved after its last 8 reports
Average move the session after a report ±2.9%
Oct 28, 2026Time not announced−3.4%
Jul 1, 2026After the close+3.0%
Apr 6, 2026Time not announced−2.8%
Jan 13, 2026After the close−5.0%
Oct 14, 2025After the close−1.1%
Jul 7, 2025After the close+3.3%
May 1, 2025Time not announced−0.1%
Feb 12, 2025Time not announced−4.3%
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha's call on BIIBStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in

Analyst Ratings & Price Targets

Analyst Ratings →
AI Starter and AI Pro
Full analyst coverage on BIIB
  • Every upgrade, downgrade and initiation as it happens
  • Every price target change, raised or cut
  • Consensus rating with the average, high and low targets
  • Each firm's full rating history on BIIB

Technical Analysis

BIIB · as of the Nov 20 close · updated each morning
Uptrend

The stock sits between its 20 and 50 day averages. It is 17% above its 200 day average, so the longer trend is still up. Momentum is neutral (RSI 54). The nearest support is the Pivot S1 at $247.42, and the nearest resistance the Pivot at $250.21.

Short trendBullish
Long trendBullish
MomentumNeutral
StretchNormal
VolatilityNormal, 2.9%/day
Key levels
$261.0052 week high+4.6%
$254.41Swing high (Oct 22)+1.9%
$252.38Pivot R1+1.1%
$250.6520 day average+0.4%
$250.21Pivot+0.2%
$249.59Last close
$247.42Pivot S1−0.9%
$243.03Swing low (Oct 28)−2.6%
$236.8350 day average−5.1%
$223.15100 day average−10.6%
$206.87200 day average−17.1%
$160.3652 week low−35.8%
Indicators
RSI (14)54.05Middle of its rangeNeutral
MACD3.62Below its signal lineBearish
Stochastic44.6Middle of its rangeNeutral
ADX (14)22.6Weak trend
Williams %R-54.3Oversold below −80, overbought above −20Neutral
CCI (20)-28.7Oversold below −100, overbought above 100Neutral
Rate of change+0.5%Change over 10 sessionsBullish
ATR (14)$7.20Typical daily range, 2.9% of price
MA 10Below
MA 20Below
MA 50Above
MA 100Above
MA 200Above
What happened before, for BIIB

What happened before

See how BIIB did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.

November seasonalityHow BIIB usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.

Seasonality

How BIIB has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2005.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Whale options flow for BIIBHow many large options trades hit BIIB, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in

See today’s whale options flow across the market →

Dark Pool

30D
Prints
Notional
Largest print
Loading…

BIIB Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Neutral
Strongly bearishNeutralStrongly bullish
  • ▲501 buying vs 406 selling
  • ▼Held by funds -1.4 pts
  • ▲Funds holding +16
  • ●Superinvestors: 2 added, 2 cut
  • ▼Put/call 0.48 to 0.77
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding1,0621,046+1.5%
In funds' top 10139+44.4%
Held by funds94.9%96.3%−1.4 pts
New / increased93 / 408110 / 426−6.5%
Reduced / sold out336 / 70293 / 84+7.7%
Put/call ratio0.770.48+61.5%
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See BIIB institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

BIIB Insider Trading

All filings →
Insider trading · 12 months
Insiders are net sellers
Bought$5851 buy · 1 insider
Sold$905K3 sales · 2 insiders
100% of the selling was under pre-arranged trading plans.
2026-02 bought $5852026-02 sold $666K2026-08 sold $240KDecMarJunSep
BoughtSoldlast 12 months
Trade dateInsiderTypeSharesPriceValue
Aug 4Lloyd MinorDirectorSale plan1,186$202.15$240K
Feb 12Nicole MurphyHead of Pharm Ops and TechBuy3$195.04$585
Feb 9Priya SinghalHead of DevelopmentSale plan2,660$199.83$532K
Feb 2Priya SinghalHead of DevelopmentSale plan748$179.30$134K
Sep 2, 2025Priya SinghalHead of DevelopmentSale plan517$133.55$69K
Jul 8, 2025Rachid IzzarHead of Global Product Strat.Sale plan2,223$135.00$300K
Every insider buy and sale for BIIB over 2 years, with a link to each SEC filing. AI Pro members can get an alert the moment an insider trades.See BIIB insider trades →

From SEC Form 4 filings by BIIB's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.

BIIB Stock Buybacks

See all S&P 500 buybacks →
Spent, 12 months
—
 
Left in program
$2.0B
5.6% of value
Shares outstanding, 12 months
+0.8%
More shares
Last quarter
$0
Sep 2026
Avg price paid, last quarter
—
 
S&P 500 rank by spending
—
 
For membersMonth by month buying, shares and the average price paid each month are shown to AI Starter and AI Pro members.

From the company's 10-Q filed Oct 28, 2026. Quarters are the company's own fiscal quarters. Yield and % of value use the latest close. Buybacks are not a forecast: in our testing, the biggest buyers did about the same as the average S&P 500 stock.

AI Auto Pilots

Paper trading

StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether BIIB is in one of them and how their past BIIB trades turned out.

BIIB in the AI portfolios
Loading…

BIIB News Tone and Price

Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered BIIB in an article yet. Here's the latest on the wider market.

BIIB in the news

BIIB Congress Trades

All congress trades →
Trades, 12 months
11
Buys
7
64%
Sells
4
36%
People
5
Last filed Oct 7
Who traded BIIB · since 2013
Latest 5 filings of 102
Maria Elvira SalazarSell (partial)
$1K – $15KTraded Sep 24, 2026Filed Oct 7, 2026
$1K – $15KTraded Sep 11, 2026Filed Oct 7, 2026
$1K – $15KTraded Sep 4, 2026Filed Oct 7, 2026
$1K – $15KTraded Aug 18, 2026Filed Sep 1, 2026
$1K – $15KTraded Mar 27, 2026Filed Jul 21, 2026
PersonTypeAmountTradedFiledDelay
Maria Elvira SalazarR · FLSell (partial)$1K – $15KSep 24, 2026Oct 7, 202613 d
Ro KhannaD · CASell$1K – $15KSep 11, 2026Oct 7, 202626 d
Ro KhannaD · CABuy$1K – $15KSep 4, 2026Oct 7, 202633 d
Kevin HernR · OKSell$1K – $15KAug 18, 2026Sep 1, 202614 d
Alan ArmstrongR · OKBuy$1K – $15KMar 27, 2026Jul 21, 2026116 d

From official House and Senate disclosure reports, filed up to 45 days after the trade and shown in dollar ranges. Not investment advice. Use limited by 5 U.S.C. 13107. About this data

About Biogen

Biogen is a biopharmaceutical company based in Cambridge, Massachusetts. It discovers, develops and sells medicines for serious and complex diseases, with a focus on neurology, specialized immunology and rare diseases. Its products include treatments for multiple sclerosis, spinal muscular atrophy, Friedreich's ataxia and ALS, along with biosimilars of widely used biologic drugs. Its customers include patients and healthcare providers, and it also works with partners such as Eisai and Genentech on other medicines.

Headquarters
Cambridge, MA
Founded
1978